Related Experiment Videos
Distant metastases in differentiated thyroid carcinomas: a clinical and pathologic study.
Y Mizukami1, T Michigishi, A Nonomura
1Department of Nuclear Medicine, Kanazawa University Hospital, Japan.
Human Pathology
|March 1, 1990
Summary
Distant metastases occurred in 6.6% of differentiated thyroid carcinoma patients. Iodine-131 uptake in metastases predicted better survival, suggesting thyroglobulin immunostaining may guide therapy effectiveness.
Area of Science:
- Oncology
- Endocrinology
- Pathology
Background:
- Differentiated thyroid carcinoma (DTC) can metastasize distantly.
- Understanding metastatic patterns and predictors of outcome is crucial for DTC management.
Purpose of the Study:
- To analyze the incidence, characteristics, and outcomes of distant metastases in DTC.
- To evaluate the role of iodine-131 (131I) uptake and thyroglobulin immunoreactivity in predicting treatment response.
Main Methods:
- Retrospective review of 514 DTC patients treated between 1970-1987.
- Histopathological reclassification of primary and metastatic tumors.
- Assessment of 131I uptake and thyroglobulin immunostaining in metastatic lesions.
Main Results:
- Distant metastases were found in 6.6% of patients, most commonly in lungs and bones.
- 131I uptake in metastases was observed in 21/32 patients, correlating with better 10-year survival (70% vs. 40%).
- Thyroglobulin immunoreactivity in metastases correlated with 131I absorption.
Conclusions:
- Distant metastases in DTC are relatively uncommon but can be fatal.
- 131I uptake in metastatic lesions is a significant predictor of improved survival.
- Thyroglobulin immunostaining may help predict the efficacy of 131I therapy for metastatic DTC.